Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a common procedure in which blood flow is restored to the legs and feet due to symptomatic PAD. The application is based on data from the VOYAGER PAD study, which showed XARELTO® (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major cardiovascular (CV) and limb events, with similar rates of Thrombolysis In Myocardial Infarction (TIMI) major bleeding.CLICK TO TWEET: @JanssenUS announces sNDA submission to @US_FDA in #peripheralarterydisease #PAD. Learn more: https://bit.ly/3koBvL3. “Various antithrombotic regimens have been evaluated for short- and long-term prevention of major vascular events in patients with PAD, but only rivaroxaban in combination with aspirin has demonstrated a significant benefit over aspirin alone,” said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular &a...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Allergy & Immunology | Anesthesia | Anesthesiology | Antiphospholipid Syndrome | Aspirin | Atrial Fibrillation | Babies | Babies Heart Conditions | Back Pain | Bleeding | Brain | Breastfed | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Centers for Disease Control and Prevention (CDC) | Child Development | Children | Chronic Pain | Clopidogrel | Complementary Medicine | Conferences | Cough | Coumadin | Dentistry | Diabetes | Diabetes Type 2 | Emergency Medicine | Endocrinology | Epistaxis (Nosebleeds) | Food and Drug Administration (FDA) | Headache | Health Management | Heart | Heart Attack | Heart Transplant | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Herbs | Hospitals | Hughes Syndrome | Hypertension | Incontinence | Infectious Diseases | Ischemic Stroke | Kidney Transplant | Learning | Legislation | Liver | Liver Transplant | Lung Transplant | Medicare | Men | Milk | Neurology | Neuroscience | Neurosurgery | New Drug Applications | Pain | Pain Management | Peripheral Vascular Disease (PVD) | Pharmaceuticals | Plavix | Pregnancy | Profits and Losses | Pulmonary Hypertension | Pulmonary Thromboembolism | Science | Smokers | Sodium | Statistics | Stroke | Study | Thrombosis | Universities & Medical Training | Urology & Nephrology | Vaccines | Vitamin A | Vitamins | Warfarin | Warnings | Women